I was unable to locate any evidence specifically about a "MOTIV study" (Medical Outcome Treatment In Validation) in the provided materials. The evidence provided discusses various topics including prehabilitation exercise, osteoarthritis management, pain management, technology-based interventions, supportive care in lung cancer, tonsillectomy pain management, non-pharmacological treatments in dementia, stroke prevention in hypertension, guideline implementation in community pharmacy, coronary artery bypass graft surgery guidelines, and amlodipine clinical trials (including studies named PREVENT, CAMELOT, and PRAISE-2).
What I Found Instead
The evidence includes several cardiovascular studies with amlodipine:
CAMELOT study: Enrolled 1,318 patients with documented coronary artery disease, showing amlodipine (5-10 mg daily) reduced composite cardiovascular endpoints by 31% (hazard ratio 0.691, p=0.003), primarily through reducing hospitalizations for angina (42% reduction) and coronary revascularization procedures (27% reduction) 1.
PREVENT study: Involved 825 patients with angiographically documented coronary artery disease followed for 3 years, though it did not show significance on the primary objective of coronary luminal diameter change 1.
PRAISE-2 study: Randomized patients with NYHA Class III/IV heart failure without ischemic disease, showing no statistically significant difference in all-cause mortality between amlodipine and placebo 1.
Recommendation
If you are asking about implementing findings from motivational interviewing studies (which appeared in the research evidence), motivational interviewing demonstrates significant effectiveness across multiple health behaviors and should be implemented by trained healthcare professionals using structured sessions focusing on patient autonomy, competence, and relatedness 2, 3.
Please clarify which specific "MOTIV study" you are referring to, as this acronym does not appear in the provided evidence base.